NEW YORK, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins Dr. Ariel Katz, President & Chief Executive Officer, Enzymotec Ltd. [ENZY] to discuss the company's industry, strategy, financials and positioning.
Click here to view video: http://www.media-server.com/m/p/c2ux9i5h
Dr. Ariel Katz, President & Chief Executive Officer:
Dr. Ariel Katz joined Enzymotec in August 2000 as President and Chief Executive Officer. He has also headed our VAYA Pharma segment since January 2012. Prior to joining Enzymotec, Dr. Katz held various positions with the Dead Sea Bromine Group of Israel Chemicals Ltd. for 14 years, including senior positions in research and development, plant management, marketing and business development. Dr. Katz holds a bachelor's degree in chemistry and an M.Sc. in economic management, both from Ben-Gurion University of the Negev, Beer Sheva, Israel, and a PhD in engineering in the field of artificial intelligence from Exeter University, UK. From 2003 until 2010 Dr. Katz was a guest lecturer in the Biotechnology Department in the Technion - Israel Institute of Technology, Haifa, Israel.
About Enzymotec Ltd:
We are a leading global supplier of specialty lipid-based products and solutions. We develop, manufacture and market innovative bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies. We deliver our products and solutions through the following two reportable segments:
1. Nutrition segment: This segment develops and manufactures nutritional ingredients for infant formulas and dietary supplements. These ingredients include InFat - which is sold and marketed by Advanced Lipids, our joint venture with AAK, InFat is a proprietary, clinically-proven infant formula fat ingredient that more closely resembles human breast milk fat to facilitate healthy infant development. Other ingredients are premium phospholipid-based bioactive ingredients for nutritional supplements. Our best-selling nutritional ingredient for dietary supplements is krill oil, which provides the benefits of omega-3 fatty acids. Our other nutritional ingredients for dietary supplements are targeted at improving brain health and providing benefits in memory, learning abilities and concentration.
2. VAYA Pharma segment: This segment develops, manufactures and sells branded lipid-based medical foods for the dietary management of medical disorders and common diseases. This is a research-based, specialty pharmaceutical segment, which currently offers medical foods products for the cardiovascular and neurological markets. Our VAYA Pharma products are currently the only products sold by us for use by end users.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 888/534-0565.